PORTLAND, Ore., March 7 /PRNewswire-FirstCall/ -- Bioject Medical
Technologies Inc. (Nasdaq: BJCT), a leading developer of needle-free drug
delivery systems, today announced that it has made the initial commercial
product delivery of the Derma-Vac(TM) NF Transdermal Vaccination System to
Merial Limited ("Merial"), a world-leading animal health company, for use
with its SWIVAX(TM)-MH, the first and only USDA approved swine vaccine
administered by a needle-free transdermal delivery system, which is
available exclusively from Merial.
The Derma-Vac(TM) NF device is designed for several production animals
and is being used initially by Merial in the swine market for the
SWIVAX(TM)-MH vaccine to aid in the reduction and control of respiratory
disease due to Mycoplasma hyopneumoniae (M. hyo). The device uses a
multi-dose vial, compressed air canister and marking pen. The device is
designed to give 2,000 injections per hour and marks the swine with ink
upon injection, indicating that the injection has been delivered. The
device comes with four nozzle sizes to address the full range of swine
delivery requirements from piglet to sow.
"We are pleased to have delivered the commercial launch Derma-Vac(TM)
NF devices to Merial for use with its new swine vaccine," said Jerald S.
Cobbs, Chairman of Bioject. "This device, which utilizes the
Biojector(R)2000 technology, is our first product that gives multiple
injections using a multi-dose vial. We look forward to this device being
used by Merial with other production animals."
About Bioject
Bioject Medical Technologies Inc., based in Portland, Oregon, is an
innovative developer and manufacturer of needle-free drug delivery systems.
Needle-free injection works by forcing medication at high speed through a
tiny orifice held against the skin. This creates a fine stream of
high-pressure fluid penetrating the skin and depositing medication in the
tissue beneath. The Company is focused on developing mutually beneficial
agreements with leading pharmaceutical, biotechnology, and veterinary
companies.
This press release contains a forward-looking statement within the
meaning of the Private Securities Litigation Reform Act of 1995, including
statements regarding the use of the Derma-Vac(TM) NF device by Merial with
other production animals. Such forward-looking statements involve known and
unknown risks, uncertainties and other factors that may cause the actual
results, performance or achievements of the Company, or industry results,
to be materially different from any future results, performance, or
achievements expressed or implied by such forward-looking statements. Such
risks, uncertainties and other factors include, without limitation, the
risk that the products will not be accepted by the market; the risk that
the Company may be unable to produce its products at a unit cost necessary
for the products to be competitive in the market; and the risk that the
Company may be unable to comply with the extensive government regulations
applicable to its business. Readers of this press release are referred to
the Company's filings with the Securities and Exchange Commission,
including the Company's reports on Form 10-K and Forms 10-Q for further
discussions of factors that could affect the Company's business and its
future results. Forward-looking statements are based on the estimates and
opinions of management on the date the statements are made. The Company
assumes no obligation to update forward-looking statements if conditions or
management's estimates or opinions should change.
For more information on Bioject, visit http://www.bioject.com.
SOURCE Bioject Medical Technologies Inc.
 back to top
Related links:
http://www.bioject.com/
CONTACT:
Jerald S. Cobbs, Chairman, +1-503-692-8001,
ext. 4161, or Chris Farrell, Vice President of Finance,
+1-503-692-8001, ext. 4132, both of Bioject Medical Technologies
Inc.
|
